Displaying 3301 - 3320 of 4794
FTC Withdraws Agency's Policy Statement on Monetary Remedies in Competition Cases; Will Rely on Existing Law
Date
The Federal Trade Commission has withdrawn the Policy Statement on Monetary Equitable Remedies in Competition Cases. The Statement was issued in 2003 and outlined a framework for determining when the...
FTC Puts Conditions on Novartis AG's Acquisition of Fougera Holdings, Inc.
Date
The Federal Trade Commission will require drug supplier Novartis AG to give up its marketing rights to four topical skin care medications, under a proposed settlement resolving charges that Novartis'...
Statement by Federal Trade Commission Chairman Jon Leibowitz on the U.S. Court of Appeals for the Third Circuit Ruling in the K-Dur 20 Matter
Date
Federal Trade Commission Chairman Jon Leibowitz issued the following statement regarding a key ruling issued today by a panel of the U.S. Court of Appeals for the Third Circuit regarding patent...
U.S. Court of Appeals Upholds FTC Opinion and Order in Polypore Matter
Date
Federal Trade Commission Commissioner Edith Ramirez issued the following statement regarding this week's ruling by the U.S. Court of Appeals for the Eleventh Circuit, which upheld the FTC's Opinion...
FTC Testimony Expresses Concern that Owners of "Standard-Essential" Patents May Obtain Injunctions Enabling Them to Hold Up Other Firms
Date
The Federal Trade Commission expressed concern to Congress about the prospect that companies that own "standard-essential" patents which are subject to commitments to license on reasonable and non...
Teva Pharmaceutical Industries Ltd., and Cephalon, Inc., In the Matter of
On 10/7/2011, the FTC required Teva Pharmaceutical Industries Ltd. to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant, as a condition of its proposed $6.8 billion acquisition of rival drug firm Cephalon, Inc. In addition, the proposed settlement requires Teva to enter into a supply agreement that will allow a competing firm to sell a generic version of Cephalon’s wakefulness drug Provigil in 2012. On 7/3/2012, the FTC issued its final order. The final amended FTC order resolving the charges requires Teva to sell the rights and assets related to a generic cancer pain drug and a generic muscle relaxant to Par Pharmaceuticals, Inc. It also requires Teva to enter into a supply agreement that will allow Par to sell a generic version of Cephalon's wakefulness drug Provigil in 2012.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
111 0166
FTC Approves Amended Final Order Settling Charges that Teva's Proposed Acquisition of Cephalon was Anticompetitive in Markets for Several Generic Drugs
Date
Following a public comment period, the Federal Trade Commission has approved an amended final order settling charges that Teva Pharmaceutical Industries, Ltd.'s proposed acquisition of rival Cephalon...
FTC Closes Its Investigation Into Sony/ATV Music Publishing's Proposed Acquisition of EMI Music Publishing
Date
The Federal Trade Commission has closed its nonpublic investigation of Sony/ATV Music Publishing's proposed acquisition of EMI Music Publishing, without taking any action. Accordingly, the deal may...
FTC Announces Pet Medications Workshop; Will Explore Competition and Consumer Protection Issues Related to the Pet Medications Industry
Date
On Tuesday, October 2, 2012, the Federal Trade Commission will host a workshop to examine the ways pet medications are distributed to consumers, and how these practices affect consumer choice and...
Perrigo Company and Paddock Laboratories, Inc., In the Matter of
On 7/26/2011, the Commission required generic drug manufacturers Perrigo Company and Paddock Laboratories, Inc. to sell six generic drugs under a proposed settlement resolving charges that Perrigo’s proposed $540 million acquisition of Paddock would be anticompetitive. The proposed settlement also contains provisions to ensure future competition in the market for generic testosterone gel product. On 6/26/2012, the FTC issued a modified final order that required the companies to sell six generic drugs to Watson Pharmaceuticals, Inc.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
111 0083
Docket Number
C-4329
FTC Issues Modified Final Order Settling Charges that Perrigo's Acquisition of Paddock Laboratories Was Anticompetitive in Market for Generic Pharmaceuticals
Date
Following a public comment period, the Federal Trade Commission has issued a modified final order settling charges that Perrigo Company's $540 million acquisition of Paddock Laboratories, Inc., as...
FTC Puts Conditions on Konkinlijke Ahold's Acquisition of Genuardi's Supermarkets
Date
The Federal Trade Commission will require Koninklijke Ahold N.V., the parent company of Giant Food Stores, LLC, to sell a supermarket outside of Philadelphia, Pennsylvania, to settle charges that its...
FTC Approves Final Order Settling Charges that Kinder Morgan's Proposed Acquisition of El Paso Corporation was Anticompetitive in Several Natural Gas Pipeline Markets
Date
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Kinder Morgan Inc.'s proposed acquisition of El Paso Corporation would have been...
FTC Approves FY 2011 HSR Premerger Notification Report Showing 24 Percent Increase in Filings Compared to FY 2010
Date
The Federal Trade Commission, with the concurrence of the Department of Justice's Assistant Attorney General for Antitrust, released the agencies' fiscal year 2011 report on their review of mergers...
FTC Puts Conditions on Johnson & Johnson's Proposed Acquisition of Synthes, Inc.
Date
The Federal Trade Commission will require Johnson & Johnson (J&J) to sell its system for surgically treating serious wrist fractures, resolving charges that J&J's proposed $21.3 billion acquisition of...
Displaying 3301 - 3320 of 4794